Skip to main content
. 2022 Mar 28;14(4):723. doi: 10.3390/pharmaceutics14040723

Figure 3.

Figure 3

Best corrected visual acuity (BCVA) and central macular thickness (CMT) evolutions depending on need for additional treatment or not.